Zydus Lifesciences‘ share price continued its upward momentum for a second straight day, climbing 1% in early trading on 15 April after receiving approval from the US Food and Drug Administration (USFDA) for its Jaythari (Deflazacort) tablets.
According to an exchange filing, the company will manufacture Jaythari tablets, which are available in 6 mg, 18 mg, 30 mg, and 36 mg strengths at its facility in Italy operated by Doppel Farmaceutici S.r.l.
Deflazacort is a corticosteroid used to treat Duchenne muscular dystrophy (DMD) in patients aged five years and older.
With this latest approval, the Zydus Group now holds a total of 424 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since it began filing in FY 2003-04.
Additionally, Zydus MedTech, a wholly owned subsidiary, established a new entity named Zydus MedTech (France) SAS on 10 April 2025.
The stock recorded a 52-week high of Rs 1,323.90 on 9 August 2024 and a 52-week low of Rs 797.05 on 7 April 2025.
At 3:30 pm, the shares of Zydus Lifesciences closed 1.17% higher at Rs 879.05 on NSE.
Zydus Lifesciences Ltd Insights? Let the Analyst Guide You.
Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!
